[{"data":1,"prerenderedAt":142},["ShallowReactive",2],{"drug-fludarabine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":59,"warnings":60,"renal":68,"monitoring":78,"interactions":79,"review":80,"examples":83,"atc":91,"iran":93,"links":109,"populations":127,"usApproval":137},"fludarabine",1,{"fa":7,"en":8},"فلودارابین","Fludarabine","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌متابولیت پورینی","Purine antimetabolite",[14],{"name":15,"market":16},"Fludara","US",[18,19,7],"fludara","فلودارا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"inj-25","injection","iv","25 mg\u002FmL, 50 mg\u002F2 mL vial",{"amount":27,"unit":28,"perVolumeMl":5},25,"mg",[16],[31],{"source":32,"section":33},"fda-fludarabine","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":47,"durationDays":50,"notes":52},"cll","chronic-lymphocytic-leukemia",{"fa":39,"en":40},"CLL سلول B (همراه سیکلوفسفامید و ریتوکسیماب) — ۲۵ mg\u002Fm² وریدی ۳۰ دقیقه، روز ۱ تا ۳ هر ۲۸ روز، ۶ دوره","B-cell CLL (with cyclophosphamide and rituximab) — 25 mg\u002Fm² IV over 30 min on days 1–3 every 28 days, 6 cycles",{"minAge":42},{"value":43,"unit":44},18,"year","bsa",{"perM2PerDay":27,"dividedDoses":5},[48],{"source":32,"section":49},"2.1",{"min":51,"max":51},3,[53],{"text":54,"refs":57},{"fa":55,"en":56},"فقط زیر نظر پزشک متخصص شیمی‌درمانی و در مرکز مجهز. عدد ماشین‌حساب = mg\u002Fm² برچسب × سطح بدن (Mosteller)؛ پروتکل، فاصله دوره‌ها، تنظیم بر اساس CBC و عملکرد کلیه\u002Fکبد با تیم انکولوژی.","Only under an oncologist in an equipped centre. Calculator = label mg\u002Fm² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal\u002Fhepatic function rest with the oncology team.",[58],{"source":32,"section":49},[],[61],{"text":62,"refs":65},{"fa":63,"en":64},"سمیت عصبی وابسته به دوز (کما، تشنج)؛ سرکوب مغز استخوان؛ سیتوپنی خودایمنی؛ GVHD ناشی از تزریق خون (فقط خون اشعه‌دیده)؛ سندرم لیز تومور؛ سمیت ریوی با پنتوستاتین؛ واکسن زنده ممنوع؛ سمیت جنینی.","Dose-dependent neurotoxicity (coma, seizures); myelosuppression; autoimmune cytopenias; transfusion-associated GVHD (irradiated blood only); tumour lysis syndrome; pulmonary toxicity with pentostatin; no live vaccines; embryo-fetal toxicity.",[66],{"source":32,"section":67},"5",[69],{"egfrBelow":70,"severity":71,"text":72,"refs":75},80,"warn",{"fa":73,"en":74},"ClCr ۵۰ تا ۷۹: ۲۰ mg\u002Fm²؛ ۳۰ تا ۴۹: ۱۵ mg\u002Fm²؛ زیر ۳۰: طبق جدول ۱.","CrCl 50–79: 20 mg\u002Fm²; 30–49: 15 mg\u002Fm²; under 30: per Table 1.",[76],{"source":32,"section":77},"2.2, Table 1",[],[],{"status":81,"reviewer":82,"date":82},"unverified",null,[84],{"regimen":36,"formulation":22,"input":85,"expect":88},{"ageYears":86,"weightKg":70,"heightCm":87},65,180,{"perDose":89,"mlPerDose":90},50,2,[92],"L01BB05",{"status":94,"forms":95,"refs":104},"registered",[96,100],{"code":97,"en":98,"fa":99},"00542","FLUDARABINE PHOSPHATE 50MG VIAL","ویال فلودارابین فسفات ۵۰ میلی‌گرم",{"code":101,"en":102,"fa":103},"52342","FLUDARABINE PHOSPHATE INJECTION, SOLUTION PARENTERAL 25 mg\u002F1mL 2 mL","محلول تزریقی فلودارابین فسفات ۲۵ میلی‌گرم \u002F ۱ میلی‌لیتر ۲ میلی‌لیتر",[105],{"source":106,"section":107,"url":108},"darooyab-generic","G-1002\u002FFludarabine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1002\u002FFludarabine",[110,114,118,122,125],{"kind":111,"url":112,"label":113},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=220196","ANDA220196",{"kind":115,"url":116,"label":117},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=291f6ee2-f5d2-ae6c-e063-6294a90a5951","FDA Fludarabine",{"kind":119,"url":120,"label":121},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa692003.html","Fludarabine Injection",{"kind":123,"url":124,"label":92},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01BB05",{"kind":126,"url":108,"label":8},"darooyab",{"pregnancy":128},{"level":129,"text":130,"quote":133,"refs":134},"avoid",{"fa":131,"en":132},"برچسب: می‌تواند به جنین آسیب برساند؛ پیشگیری مؤثر لازم است.","Label: can cause fetal harm; effective contraception required.","Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.",[135],{"source":32,"section":136},"5.8",{"kind":138,"refs":139,"id":113},"ANDA",[140],{"source":32,"section":141},"SPL approval \u002F marketing category",1792444399397]